Portal de Periódicos da CAPES

Guillain‐Barré Syndrome in an Australian State Using Both mRNA and Adenovirus‐Vector SARS‐CoV ‐2 Vaccines

2021; Wiley; Volume: 90; Issue: 5 Linguagem: Inglês

10.1002/ana.26218

1531-8249

Joshua Osowicki, Hannah Morgan, Adele Harris, Nigel W. Crawford, Jim Buttery, Lynette Kiers,

SARS-CoV-2 and COVID-19 Research

Annals of NeurologyVolume 90, Issue 5 p. 856-858 Letter to the Editor Guillain-Barré Syndrome in an Australian State Using Both mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines Joshua Osowicki PhD, Corresponding Author Joshua Osowicki PhD [email protected] orcid.org/0000-0002-9432-6700 Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, VIC, Australia Department of General Medicine, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia co-authors Hannah Morgan and Joshua Osowicki contributed equally to this work. Address correspondence to Dr Osowicki, Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Parkville, 3052, VIC, Australia. E-mail: [email protected]Search for more papers by this authorHannah Morgan MPH, Hannah Morgan MPH Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, VIC, Australia co-authors Hannah Morgan and Joshua Osowicki contributed equally to this work.Search for more papers by this authorAdele Harris RN, Adele Harris RN Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, VIC, AustraliaSearch for more papers by this authorNigel W. Crawford PhD, Nigel W. Crawford PhD Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, VIC, Australia Department of General Medicine, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia Department of Paediatrics, The University of Melbourne, Melbourne, VIC, AustraliaSearch for more papers by this authorJim P. Buttery PhD, Jim P. Buttery PhD Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, VIC, Australia Department of General Medicine, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia Centre for Health Analytics, Royal Children's Hospital Melbourne, Melbourne, VIC, AustraliaSearch for more papers by this authorLynette Kiers MD, Lynette Kiers MD Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia Department of Medicine, Faculty of Medicine, Health and Dentistry, The University of Melbourne, Melbourne, VIC, AustraliaSearch for more papers by this author Joshua Osowicki PhD, Corresponding Author Joshua Osowicki PhD [email protected] orcid.org/0000-0002-9432-6700 Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, VIC, Australia Department of General Medicine, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia co-authors Hannah Morgan and Joshua Osowicki contributed equally to this work. Address correspondence to Dr Osowicki, Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Parkville, 3052, VIC, Australia. E-mail: [email protected]Search for more papers by this authorHannah Morgan MPH, Hannah Morgan MPH Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, VIC, Australia co-authors Hannah Morgan and Joshua Osowicki contributed equally to this work.Search for more papers by this authorAdele Harris RN, Adele Harris RN Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, VIC, AustraliaSearch for more papers by this authorNigel W. Crawford PhD, Nigel W. Crawford PhD Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, VIC, Australia Department of General Medicine, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia Department of Paediatrics, The University of Melbourne, Melbourne, VIC, AustraliaSearch for more papers by this authorJim P. Buttery PhD, Jim P. Buttery PhD Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, VIC, Australia Department of General Medicine, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia Centre for Health Analytics, Royal Children's Hospital Melbourne, Melbourne, VIC, AustraliaSearch for more papers by this authorLynette Kiers MD, Lynette Kiers MD Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia Department of Medicine, Faculty of Medicine, Health and Dentistry, The University of Melbourne, Melbourne, VIC, AustraliaSearch for more papers by this author First published: 15 September 2021 https://doi.org/10.1002/ana.26218Citations: 15 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Allen CM, Ramsamy S, Tarr AW, et al. Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol 2021; 90: 315–318. https://doi.org/10.1002/ana.26144 10.1002/ana.26144 CASPubMedWeb of Science®Google Scholar 2Maramattom BV, Krishnan P, Paul R, et al. Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine. Ann Neurol 2021; 90: 312–314. https://doi.org/10.1002/ana.26143 10.1002/ana.26143 CASPubMedWeb of Science®Google Scholar 3Crawford NW, Cheng A, Andrews N, et al. Guillain-Barre syndrome following pandemic (H1N1) 2009 influenza a immunisation in Victoria: a self-controlled case series. Med J Aust 2012; 197: 574–578. 10.5694/mja12.10534 PubMedWeb of Science®Google Scholar 4van Koningsveld R, Steyerberg EW, Hughes RA, et al. A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 2007; 6: 589–594. 10.1016/S1474-4422(07)70130-8 PubMedWeb of Science®Google Scholar 5Lunn MP, Cornblath DR, Jacobs BC, et al. COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. Brain 2021; 144: 357–360. 10.1093/brain/awaa444 PubMedWeb of Science®Google Scholar 6Márquez Loza AM, Holroyd KB, Johnson SA, et al. Guillain- Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality. Neurology 2021. (Online ahead of print). https://pubmed.ncbi.nlm.nih.gov/33824169/ Google Scholar Citing Literature Volume90, Issue5November 2021Pages 856-858 ReferencesRelatedInformation